ZA200402844B - Rosuvastatin in pre demented states. - Google Patents
Rosuvastatin in pre demented states. Download PDFInfo
- Publication number
- ZA200402844B ZA200402844B ZA200402844A ZA200402844A ZA200402844B ZA 200402844 B ZA200402844 B ZA 200402844B ZA 200402844 A ZA200402844 A ZA 200402844A ZA 200402844 A ZA200402844 A ZA 200402844A ZA 200402844 B ZA200402844 B ZA 200402844B
- Authority
- ZA
- South Africa
- Prior art keywords
- rosuvastatin
- dementia
- risk
- demented
- patient
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims description 47
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims description 34
- 229960000672 rosuvastatin Drugs 0.000 title claims description 34
- 238000000034 method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 15
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 12
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 9
- 102100029470 Apolipoprotein E Human genes 0.000 description 8
- 101710095339 Apolipoprotein E Proteins 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 5
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 5
- 201000004810 Vascular dementia Diseases 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 208000027061 mild cognitive impairment Diseases 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101100075486 Caenorhabditis elegans lrp-1 gene Proteins 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 101150084157 lrp-1 gene Proteins 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010855 neuropsychological testing Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000037820 vascular cognitive impairment Diseases 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- -1 3-methylglutaryl Chemical group 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 101150013552 LDLR gene Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000005249 arterial vasculature Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402844B true ZA200402844B (en) | 2005-01-24 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200402844A ZA200402844B (en) | 2001-10-19 | 2004-04-15 | Rosuvastatin in pre demented states. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (enExample) |
| EP (1) | EP1446123A1 (enExample) |
| JP (1) | JP2005505605A (enExample) |
| KR (1) | KR20040058201A (enExample) |
| CN (1) | CN1604780A (enExample) |
| AR (1) | AR036891A1 (enExample) |
| BR (1) | BR0213434A (enExample) |
| CA (1) | CA2463597A1 (enExample) |
| CO (1) | CO5580773A2 (enExample) |
| HU (1) | HUP0401798A3 (enExample) |
| IL (1) | IL161380A0 (enExample) |
| IS (1) | IS7218A (enExample) |
| MX (1) | MXPA04003631A (enExample) |
| NO (1) | NO20041840L (enExample) |
| PL (1) | PL369573A1 (enExample) |
| RU (1) | RU2004112422A (enExample) |
| SE (1) | SE0103509D0 (enExample) |
| WO (1) | WO2003032995A1 (enExample) |
| ZA (1) | ZA200402844B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US7777034B2 (en) | 2003-11-24 | 2010-08-17 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| PT1689723E (pt) | 2003-12-02 | 2011-07-06 | Teva Pharma | Padrão referência para a caracterização de rosuvastatina |
| EP1673351A1 (en) | 2004-07-13 | 2006-06-28 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| WO2006091770A2 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| KR20070062996A (ko) | 2005-08-16 | 2007-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 로수바스타틴 중간체 |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL161380A0 (en) | 2004-09-27 |
| KR20040058201A (ko) | 2004-07-03 |
| HUP0401798A3 (en) | 2005-06-28 |
| SE0103509D0 (sv) | 2001-10-19 |
| US20060229321A1 (en) | 2006-10-12 |
| CO5580773A2 (es) | 2005-11-30 |
| MXPA04003631A (es) | 2004-07-30 |
| EP1446123A1 (en) | 2004-08-18 |
| BR0213434A (pt) | 2004-11-09 |
| RU2004112422A (ru) | 2005-04-10 |
| CA2463597A1 (en) | 2003-04-24 |
| WO2003032995A1 (en) | 2003-04-24 |
| AR036891A1 (es) | 2004-10-13 |
| PL369573A1 (en) | 2005-05-02 |
| WO2003032995A8 (en) | 2004-06-03 |
| CN1604780A (zh) | 2005-04-06 |
| JP2005505605A (ja) | 2005-02-24 |
| NO20041840L (no) | 2004-05-05 |
| IS7218A (is) | 2004-04-13 |
| HUP0401798A2 (hu) | 2005-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2305118T3 (es) | Uso de rosuvastatina (zd-4522) en el tratamiento de hipercolesteremia familiar heterocigota. | |
| US6180660B1 (en) | Cholesterol-lowering therapy | |
| EP3653609B1 (en) | Hydantoins that modulate bace-mediated app processing | |
| EP0671171A1 (en) | Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events | |
| JP2001517617A (ja) | 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法 | |
| JP2002529500A (ja) | ＨＭＧＣｏＡレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法 | |
| Singh et al. | Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia | |
| CN102481283A (zh) | 创伤或损伤后中枢神经系统继发性损伤的预防和治疗 | |
| Molden et al. | Simvastatin‐associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients | |
| US20060229321A1 (en) | Rosuvastatin in pre demented states | |
| US20070269513A1 (en) | Liver selective drug therapy | |
| Gardner et al. | Combination therapy with low‐dose lovastatin and niacin is as effective as higher‐dose lovastatin | |
| WO1999009967A2 (en) | Cholesterol-lowering therapy | |
| Jantarabenjakul et al. | Pharmacokinetics and safety of WHO-recommended dosage and higher dosage of levofloxacin for tuberculosis treatment in children: a pilot study | |
| AU2002332610B2 (en) | Use of atazanavir in HIV therapy | |
| AU2002332610A1 (en) | Use of atazanavir in HIV therapy | |
| AU2002347698A1 (en) | Rosuvastatin in pre demented states | |
| Kurata et al. | Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia | |
| JP2019038858A (ja) | ペマフィブラートを含有する医薬 | |
| JP4187141B2 (ja) | 新規なトロンボモジュリン発現促進剤 | |
| CN111588719A (zh) | 辛伐他汀在制备治疗新冠肺炎药物中的应用 | |
| US20250352511A1 (en) | Methods of treating focal segmental glomerulosclerosis with atrasentan | |
| Herd et al. | Acute confusional state with postoperative intravenous cefazolin | |
| Moore | Successful treatment with colesevelam HCl and pravastatin in a patient previously hospitalised with severe normal CPK myopathy on introduction of simvastatin | |
| WO2006011495A1 (ja) | 高コレステロール血症及び／又は高トリグリセリド血症治療剤 |